You are here:

aripiprazole (Abilify)

Advice

following a full submission:

aripiprazole oral (Abilify®) is accepted for restricted use within NHS Scotland.

Indication under review: treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.

SMC restriction: restricted to initiation and management under the supervision of a child/adolescent psychiatrist.

Aripiprazole demonstrated superior efficacy to placebo in reducing manic symptoms at 4 weeks.  Aripiprazole has not been directly compared to other atypical antipsychotics, none of which are licensed for this indication although they are used off-label in clinical practice.

Drug Details

Drug Name: aripiprazole (Abilify)
SMC Drug ID: 891/13
Manufacturer: Otsuka Pharmaceutical Europe
Indication: Treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.
BNF Category:
Sub Category: 4.2 Drugs used in psychoses and related disorders
Submission Type: Full submission
Status: Restricted
Date Advice Published: 9 September 2013

Back